Study of Wild-type TTR Cardiac Amyloidosis in Patients Aged 60 and Older with Unexplained Polyneuropathy

What this Trial Is About

Researchers are investigating whether chronic axonal length-dependent polyneuropathy CAP andor small-fiber neuropathy SFN might be early signs of wild-type TTR cardiac amyloidosis wtTTR-CA, a heart condition. The study aims to explore if recognizing these neuropathies can lead to faster diagnosis and better clinical outcomes for wtTTR-CA. This prospective monocentric study focuses on patients with polyneuropathy of unknown cause. Participants with CAP andor SFN, who have already undergone nerve conduction studies NCS, electromyography EMG, and Sudoscan testing, will be invited for a single combined neurology and cardiology visit. During this visit, they will undergo assessments including symptom evaluation using NTSS-6 and COMPASS31 questionnaires, physical examination scales mPND, NIS, a Kansas City Cardiomyopathy Questionnaire KCCQ, electrocardiogram ECG, and echocardiography. Retrospective data from their medical records, including previous tests and lab results, will also be reviewed. During the study visit, participants will complete questionnaires on neuropathy and cardiac symptoms and receive heart and nerve function tests. Researchers will analyze the prevalence of wild-type cardiac amyloidosis in this group over 36 months. They will also monitor symptom severity, progression, and identify warning signs that could help neurologists recognize cardiac amyloidosis earlier. The total participation involves one study visit and retrospective data analysis without long-term follow-up visits.

Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.